Palvella Therapeutics (PVLA) Net Income towards Common Stockholders (2013 - 2026)
Palvella Therapeutics (PVLA) posted quarterly Net Income towards Common Stockholders of -$15.8 million for Q1 2026, down 92.63% year-over-year from -$214.0 million in Q1 2025, and down 23.39% quarter-over-quarter from -$12.8 million in Q4 2025.
Powered by 
Analysis
Palvella Therapeutics (PVLA) Net Income towards Common Stockholders (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Net Income towards Common Stockholders for 14 consecutive years, with -$15.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 92.63% year-over-year to -$15.8 million; the TTM figure through Mar 2026 stood at -$49.4 million (down 115.65% YoY), while the FY2025 annual figure was -$41.8 million, down 139.64% from the prior year.
- Net Income towards Common Stockholders declined to -$15.8 million in Q1 2026 per PVLA's latest filing, from -$12.8 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $15.0 million in Q4 2023 and bottomed at -$16.0 million in Q1 2023.
- Historically, Net Income towards Common Stockholders has averaged -$7.8 million across 5 years, with a median of -$9.5 million in 2025.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders soared 221.65% — and 2024, when it plunged 379.33%.
- Palvella Therapeutics' Net Income towards Common Stockholders stood at -$12.3 million in 2022, then jumped by 221.65% to $15.0 million in 2023, then tumbled by 122.48% to -$3.4 million in 2024, then tumbled by 279.28% to -$12.8 million in 2025, then fell by 23.39% to -$15.8 million in 2026.
- Business Quant data shows PVLA's Net Income towards Common Stockholders at -$15.8 million in Q1 2026, -$12.8 million in Q4 2025, and -$11.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Palvella Therapeutics | 2.24 Bn | 1.93 Bn | - | -21.87 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -21.87 Mn |
| Mar 31, 2026 | -15.77 Mn |
| Dec 31, 2025 | -4.02 Mn |
| Sep 30, 2025 | -11.35 Mn |
| Jun 30, 2025 | -9.47 Mn |
| Mar 31, 2025 | -8.19 Mn |
| Dec 31, 2024 | -3.37 Mn |
| Sep 30, 2024 | -6.97 Mn |
| Jun 30, 2024 | -4.37 Mn |
| Mar 31, 2024 | -2.73 Mn |
| Dec 31, 2023 | 13.84 Mn |
| Sep 30, 2023 | -11.26 Mn |
| Jun 30, 2023 | 2.55 Mn |
| Mar 31, 2023 | -15.15 Mn |
| Dec 31, 2022 | -11.17 Mn |
| Sep 30, 2022 | -11.93 Mn |
| Jun 30, 2022 | -12.20 Mn |
| Mar 31, 2022 | -7.46 Mn |
| Dec 31, 2021 | -11.01 Mn |
| Sep 30, 2021 | -19.01 Mn |